A single-center, randomized, open label trial assessing 48 weeks of exenatide in 50 participants with Multiple System Atrophy (randomly assigned 1:1 to exenatide or control) reports positive result (UMSARS parts I + II scores at 48 weeks) onlinelibrary.wi…
- Exenetide had promise as a disease modifying agent in #Parkinsonsdisease. How about #MSA? - Single center, *open-label* 48 wk trial lower change in UMSARS score over tme. - Treatment had no impact on objective findings. - Placebo/bias effects highly …
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy onlinelibrary.wiley.com/doi/10.1002/...
Exenatide qw over 48 weeks and Multi-system Atrophy onlinelibrary.wiley.com/doi/10.1002/...